Business Wire

JPT Peptide Technologies Launches The Human Proteome Peptide Catalog

Del

JPT Peptide Technologies (JPT) announces the launch of The Human Proteome Peptide Catalog, the first and most comprehensive online resource for validated reference peptides in mass-spectrometry based proteomics.

The new repository provides fast access to >400.000 light & heavy proteotypic peptides covering essentially all proteins of the human body. Currently, a total of 19.840 proteins is matched by the peptide collection and confirmed by more than 10.000.000 validated spectra available through the database ProteomicsDB.

Holger Wenschuh, Managing Director of JPT, states: “Together with our partners within the ProteomeTools Project we have worked for several years towards the goal of translating the human proteome information into reagents and online tools to decipher the complexity of the human organism on the functional level”, adding: “We are extremely excited to make this repository available to the broad life science community enabling a completely new dimension of research and development using mass-spectrometry based proteomics approaches.”

The Human Proteome Peptide Catalog is an interactive knowledge, spectra and peptide resource that will be continuously expanded with the support of JPT’s partners at the Technical University of Munich to also address a broad level of post-translational modifications, splice-variants, mutations and more.

JPT Peptide Technologies GmbH, a wholly owned subsidiary of BioNTech AG, is an DIN ISO 9001:2015 certified research and development partner and innovative service provider for peptide related projects in immunotherapy, proteomics and drug discovery. JPT’s key technologies SPOTTM – for ultra-high-throughput peptide synthesis and screening, PepStarTM – for high-content peptide microarrays, PepTrackTM - for flexible peptide library assembly, PepMixTM – for antigen specific T-cell stimulation using peptide pools, and SpikeTidesTM/SpikeMixTM – for protein biomarker discovery and quantification accelerate research and development in areas such as cell and immunotherapy, vaccine development, biomarker discovery, peptide lead identification and optimization, and proteomics. For more information, please visit www.jpt.com.

Contact information

JPT Peptide Technologies
Dr. Holger Wenschuh
Managing Director
T +49-30-6392-5500
X +49-30-6392-5501
peptide@jpt.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46Pressemelding

The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+

Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16Pressemelding

HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati

Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)21.9.2018 05:30Pressemelding

Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been previously treated with sorafenib. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, MD, Executive Vice President, R&D and Chief Scientific Officer, Ipsen, said: “The global burden of liver cancer is increasing and despite the recent introduction of new agents, it remains the second leading cause of cancer mortality worldwide. Following today’s positive CHMP opinion and if approved by the European Commission, Cabometyx ® as monotherapy will give patients with HCC a much-needed new oral therapeutic option.” Dr Lorenza Rimassa,

Quanergy Selected as Exclusive LiDAR Partner for VRCO21.9.2018 05:00Pressemelding

Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, and VRCO, designer and manufacturer of the luxury high-end e-VTOL (electric Vertical Take-Off and Landing) craft, the NeoXcraft XP2, today announced that VRCO will exclusively use Quanergy’s S3 solid state LiDAR sensors in the testing and market release versions of the aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920006036/en/ VRCO NeoXcraft XP2 with Quanergy S3 LiDAR Sensor (Graphic: Business Wire) The NeoXcraft XP2, which VRCO and the University of Derby unveiled in late 2017 and intend to launch in 2020, is a two-passenger e-VTOL high-speed land, air, and water capable craft. The craft can scan and memorize take-off locations and store the data for use on the next approach to the same location. Quanergy’s innovative S3 solid state LiDAR sensor will be used for downward and forward

Overseas Roadshow for the IAPH Guangzhou 2019 World Ports Conference Was Held in London21.9.2018 03:08Pressemelding

Overseas roadshow for the IAPH Guangzhou 2019 World Ports Conference was successfully held in Armourer's Hall, London, UK on September 20th. Ms. Yuan Yue, Deputy Director General of Guangzhou Port Authority, met with over 100 senior representatives from British ports, ship-owners, commodity traders, shipping & service companies, shipping public policy research institutes, and other representatives from the port and shipping industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920006031/en/ Speech made by Lord Jeffrey Evans, Chairman of Maritime London (Photo: Business Wire) In her keynote speech, Ms. Yuan Yue said, “Guangzhou is the gateway city of South China and is known as the “Millennium Business Capital” and a popular destination for business and investment. At present, Guangzhou has attracted investors from over 130 countries. Nearly 300 of the world's top 500 companies have businesses and investment in Guangzho